Ocular Drug Delivery

Pharmaceutical Manufacturing Handbook: Production and Processes

Volumn , Issue , 2007, Pages 729-767

  Rupenthal, Ilva D ^a   Alany, Raid G ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Delivery technologies and clinical ophthalmology; Drug particle size in suspension formulation process; Ocular drug delivery challenges

Indexed keywords

EID: 84889860740     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470259818.ch19     Document Type: Chapter

References (240)

1. Le Bourlais, C., Acar, L., Zia, H., Sado, P. A., Needham, T., and Leverge, R. (1998), Ophthalmic drug delivery systems-Recent advances, Prog. Ret. Eye Res., 17 (1), 33-58.
2. Le Bourlais, C. A., Treupel-Acar, L., Rhodes, C. T., Sado, P. A., and Leverge, R. (1995), New ophthalmic drug delivery systems, Drug Dev. Ind. Pharm., 21 (1), 19-59.
3. Jarvinen, K., Jarvinen, T., and Urtti, A. (1995), Ocular absorption following topical delivery, Adv. Drug Deliv. Rev., 16 (1), 3-19.
4. Sasaki, H., Yamamura, K., Mukai, T., Nishida, K., Nakamura, J., Nakashima, M., et al. (1999), Enhancement of ocular drug penetration, Crit. Rev. Ther. Drug Carrier Syst., 16 (1), 85-146.
5. Baeyens, V., and Gurny, R. (1997), Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations, Pharm. Acta Helv., 72 (4), 191-202.
6. Van Haeringen, N. J. (1981), Clinical biochemistry of tears, Surv. Ophthalmol., 26 (2), 84-96.
7. Nagyova, B., and Tiffany, J. M. (1999), Components responsible for the surface tension of human tears, Curr. Eye Res., 19 (1), 4-11.
8. Tiffany, J. M. (2003), Tears in health and disease, Eye, 17 (8), 923-926.
9. Murube, J., Murube, L., and Murube, A. (1999), Origin and types of emotional tearing, Eur. J. Ophthalmol., 9 (2), 77-84.
10. Versura, P., Bonvicini, F., Caramazza, R., and Laschi, R. (1985), Scanning electron microscopy of normal human corneal epithelium obtained by scraping-off in vivo, Acta Ophthalmol., 63 (3), 361-365.
11. Klyce, S. D., and Crosson, C. E. (1985), Transport processes across the rabbit corneal epithelium: A review, Curr. Eye Res., 4 (4), 323-331.
12. Lens, A. (1999), Ocular Anatomy and Physiology, Slack, New York.
13. Ahmed, I. (2003), The noncorneal route in ocular drug delivery, in Mitra, A. K., Ed., Ophthalmic Drug Delivery Systems, 2nd ed., Marcel Dekker, New York, pp. 335-363.
14. Greaves, J. L., and Wilson, C. G. (1993), Treatment of diseases of the eye with mucoadhesive delivery systems, Adv. Drug Deliv. Rev., 11 (3), 349-383.
15. Huang, A. J. W., Tseng, S. C. G., and Kenyon, K. R. (1989), Paracellular permeability of corneal and conjunctival epithelia, Invest. Ophthalmol. Vis. Sci., 30 (4), 684-689.
16. Ahmed, I., and Patton, T. F. (1985), Importance of the noncorneal absorption route in topical ophthalmic drug delivery, Invest. Ophthalmol. Vis. Sci., 26 (4), 584-587.
17. Macha, S., Hughes, P. M., and Mitra, A. K. (2003), Overview of ocular drug delivery, in Mitra, A. K., Ed., Ophthalmic Drug Delivery Systems, 2nd ed., Marcel Dekker, New York, pp. 1-11.
18. Robinson, J. C. (1993), Ocular anatomy and physiology relevant to ocular drug delivery, in Mitra, A. K., Ed., Ophthalmic Drug Delivery Systems, Marcel Dekker, New York, pp. 29-58.
19. Mikkelson, T. J., Chrai, S. S., and Robinson, J. R. (1973), Altered bioavailability of drugs in the eye due to drug-protein interaction, J. Pharm. Sci., 62 (10), 1648-1653.
20. Stjernschantz, J., and Astin, M. (1993), Anatomy and physiology of the eye. Physiological aspects of ocular drug therapy, in Edman, P., Ed., Biopharmaceutics of Ocular Drug Delivery, CRC Press, Boca Raton, FL, pp. 1-25.
21. Hornof, M., Toropainen, E., and Urtti, A. (2005), Cell culture models of the ocular barriers, Eur. J. Pharm. Biopharm., 60 (2), 207-225.
22. Jumbe, N. L., and Miller, M. H. (2003), Ocular drug transfer following systemic drug administration, in Mitra, A. K., Ed., Ophthalmic Drug Delivery Systems, 2nd ed., Marcel Dekker, New York, pp. 109-133.
23. Urtti, A., and Salminen, L. (1993), Animal pharmacokinetic studies, in Mitra, A. K., Ed., Ophthalmic Drug Delivery Systems, Marcel Dekker, New York, pp. 121-136.
24. Duvvuri, S., Majumdar, S., and Mitra, A. K. (2003), Drug delivery to the retina: Challenges and opportunities, Expert Opin. Biol. Ther., 3 (1), 45-56.
25. Loftssona, T., and Jarvinen, T. (1999), Cyclodextrins in ophthalmic drug delivery, A dv. Drug Deliv. Rev., 36 (1), 59-79.
26. Kaur, I. P., Garg, A., Singla, A. K., and Aggarwal, D. (2004), Vesicular systems in ocular drug delivery: An overview, Int. J. Pharm., 269 (1), 1-14.
27. Lee, V. H., and Robinson, J. R. (1979), Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits, J. Pharm. Sci., 68 (6), 673-684.
28. Lee, V. H. L., and Li, V. H. K. (1989), Prodrugs for improved ocular drug delivery, Adv. Drug Deliv. Rev., 3 (1), 1-38.
29. Rojanasakul, Y., and Robinson, J. R. (1989), Transport mechanisms of the cornea: Characterization of barrier permselectivity, Int. J. Pharm., 55 (2-3), 237-246.
30. Palmgren, J. J., Toropainen, E., Auriola, S., and Urtti, A. (2002), Liquid chromatographic-electrospray ionization mass spectrometric analysis of neutral and charged polyethylene glycols, J. Chromatogr. A, 976 (1-2), 165-170.
31. Van Ooteghem, M. M. M. (1993), Formulation of ophthalmic solutions and suspensions. Problems and Advantages, in Edman, P., Ed., B iopharmaceutics of Ocular Drug Delivery, CRC Press, Boca Raton, FL, pp. 27-42.
32. Schoenwald, R. D., and Huang, H. S. (1983), Corneal penetration behavior of beta-blocking agents I: Physiochemical factors, J. Pharm. Sci., 72 (11), 1266-1272.
33. Grass, G. M., Wood, R. W., and Robinson, J. R. (1985), Effects of calcium chelating agents on corneal permeability, Invest. Ophthalmol. Vis. Sci., 26 (1), 110-113.
34. Liaw, J., Rojanasakul, Y., and Robinson, J. R. (1992), The effect of drug charge type and charge density on corneal transport, Int. J. Pharm., 88 (1-3), 111-124.
35. Sieg, J. W., and Robinson, J. R. (1975), Vehicle effects on ocular drug bioavailability: Evaluation of fluorometholone, J. Pharm. Sci., 64 (6), 931-936.
36. Kaur, I. P., and Smitha, R. (2002), Penetration enhancers and ocular bioadhesives: Two new avenues for ophthalmic drug delivery, Drug Dev. Ind. Pharm., 28 (4), 353-369.
37. Mishima, S., Gasset, A., Klyce, S. D., Jr, and Baum, J. L. (1966), Determination of tear volume and tear flow, Invest. Ophthalmol., 5 (3), 264-276.
38. Mainardes, R. M., Urban, M. C. C., Cinto, P. O., Khalil, N. M., Chaud, M. V., Evangelista, R. C., et al. (2005), Colloidal carriers for ophthalmic drug delivery, Curr. Drug Targets, 6 (3), 363-371.
39. Chrai, S. S., Patton, T. F., Mehta, A., and Robinson, J. R. (1973), Lacrimal and instilled fluid dynamics in rabbit eyes, J. Pharm. Sci., 62 (7), 1112-1121.
40. Chrai, S. S., and Robinson, J. R. (1974), Ocular evaluation of methylcellulose vehicle in albino rabbits, J. Pharm. Sci., 63 (8), 1218-1223.
41. Sieg, J. W., and Triplett, J. W. (1980), Precorneal retention of topically instilled micronized particles, J. Pharm. Sci., 69 (7), 863-864.
42. Lee, V. H. L., Urrea, P. T., Smith, R. E., and Schanzlin, D. J. (1985), O cular drug bioavailability from topically applied liposomes, Surv. Ophthalmol., 29 (5), 335-348.
43. Zimmer, A., and Kreuter, J. (1995), Microspheres and nanoparticles used in ocular delivery systems, Adv. Drug Deliv. Rev., 16 (1), 61-73.
44. Ludwig, A. (2005), The use of mucoadhesive polymers in ocular drug delivery, Adv. Drug Deliv. Rev., 57 (11), 1595-1639.
45. Ludwig, A., and Van Ooteghem, M. (1987), The influence of the osmolality on the precorneal retention of ophthalmic solutions, J. Pharm. Belg., 42 (4), 259-266.
46. Kaufman, H. E., Steinemann, T. L., Lehman, E., Thompson, H. W., Varnell, E. D., Jacob-LaBarre, J. T., et al. (1994), Collagen-based drug delivery and artificial tears, J. Ocul. Pharmacol., 10 (1), 17-27.
47. Ke, T.-L., Cagle, G., Schlech, B., Lorenzetti, O. J., and Mattern, J. (2001), Ocular bioavailability of ciprofloxacin in sustained release formulations, J. Ocul. Pharmacol. Ther., 17 (6), 555-563.
48. Meseguer, G., Buri, P., Plazonnet, B., Rozier, A., and G urny, R. (1996), Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers, J. Ocul. Pharmacol. Ther., 12 (4), 481-488.
49. Hui, H.-W., and Robinson, J. R. (1985), Ocular delivery of progesterone using a bioadhesive polymer, Int. J. Pharm., 26 (3), 203-213.
50. Lele, B. S., and Hoffman, A. S. (2000), Insoluble ionic complexes of polyacrylic acid with a cationic drug for use as a mucoadhesive, ophthalmic drug delivery system, J. Biomater. Sci. Polym. Ed., 11 (12), 1319-1331.
51. Saettone, M. F., Giannaccini, B., Ravecca, S., La Marca, F., and Tota, G. (1984), Polymer effects on ocular bioavailability-The influence of different liquid vehicles on the mydriatic response of tropicamide in humans and in rabbits, Int. J. Pharm., 20 (1-2), 187-202.
52. Herrero-Vanrell, R., Fernandez-Carballido, A., Frutos, G., and Cadorniga, R. (2000), Enhancement of the mydriatic response to tropicamide by bioadhesive polymers, J. Ocul. Pharmacol. Ther., 16 (5), 419-428.
53. Saettone, M. F., Chetoni, P., Tilde Torracca, M., Burgalassi, S., and Giannaccini, B. (1989), Evaluation of muco-adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid, Int. J. Pharm., 51 (3), 203-212.
54. Sandri, G., Bonferoni, M. C., Chetoni, P., Rossi, S., Ferrari, F., Ronchi, C., et al. (2006), Ophthalmic delivery systems based on drug-polymer-polymer ionic ternary interaction: In vitro and in vivo characterization, Eur. J. Pharm. Biopharm., 62 (1), 59-69.
55. Felt, O., Furrer, P., Mayer, J. M., Plazonnet, B., Buri, P., and Gurny, R. (1999), Topical use of chitosan in ophthalmology: Tolerance assessment and evaluation of precorneal retention, Int. J. Pharm., 180 (2), 185-193.
56. Felt, O., Baeyens, V., Buri, P., and Gurny, R. (2001), Delivery of antibiotics to the eye using a positively charged polysaccharide as vehicle, Aaps Pharmsci, 3 (4), E34.
57. Di Colo, G., Zambito, Y., Burgalassi, S., Nardini, I., and Saettone, M. F. (2004), Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin, Int. J. Pharm., 273 (1-2), 37-44.
58. Di Colo, G., Zambito, Y., Burgalassi, S., and Saettone, M. F. (2003), Effects of chitosan and of its N-trimethyl and N-carboxymethyl derivatives on the ocular pharmacokinetics of ofloxacin in rabbits, paper presented at the 30th International Symposium on Controlled Release of Bioactive Materials, Glasgow, Scottland.
59. Davies, N. M., Farr, S. J., Hadgraft, J., and Kellaway, I. W. (1991), Evaluation of mucoadhesive polymers in ocular drug delivery. I. Viscous solutions, Pharm. Res., 8 (8), 1039-1043.
60. Edsman, K., Carlfors, J., and Harju, K. (1996), Rheological evaluation and ocular contact time of some carbomer gels for ophthalmic use, Int. J. Pharm., 137 (2), 233-241.
61. Hartmann, V., and Keipert, S. (2000), Physico-chemical, in vitro and in vivo characterisation of polymers for ocular use, Pharmazie, 55 (6), 440-443.
62. Burgalassi, S., Chetoni, P., Panichi, L., Boldrini, E., and Saettone, M. F. (2000), Xyloglucan as a novel vehicle for timolol: Pharmacokinetics and pressure lowering activity in rabbits, J. Ocul. Pharmacol. Ther., 16 (6), 497-509.
63. Ceulemans, J., Vinckier, I., and Ludwig, A. (2002), T he use of xanthan gum in an ophthalmic liquid dosage form: Rheological characterization of the interaction with mucin, J. Pharm. Sci., 91 (4), 1117-1127.
64. Verschueren, E., Van Santvliet, L., and Ludwig, A. (1996), Evaluation of various carrageenans as ophthalmic viscolysers, STP Pharma Sci., 6 (3), 203-210.
65. Albasini, M., and Ludwig, A. (1995), Evaluation of polysaccharides intended for ophthalmic use in ocular dosage forms, Farmaco, 50 (Sept.), 633-642.
66. Snibson, G. R., Greaves, J. L., Soper, N. D., Prydal, J. I., Wilson, C. G., and Bron, A. J. (1990), Precorneal residence times of sodium hyaluronate solutions studied by quantitative gamma scintigraphy, Eye, 4 (4), 594-602.
67. Snibson, G. R., Greaves, J. L., Soper, N. D., Tiffany, J. M., Wilson, C. G., and B ron, A. J. (1992), Ocular surface residence times of artificial tear solutions, Cornea, 11 (4), 288-293.
68. Debbasch, C., De La Salle, S. B., Brignole, F., Rat, P., Warnet, J. M., and Baudouin, C. (2002), Cytoprotective effects of hyaluronic acid and Carbomer 934P in ocular surface epithelial cells, Invest. Ophthalmol. Vis. Sci., 43 (11), 3409-3415.
69. Oechsner, M., and Keipert, S. (1999), Polyacrylic acid/polyvinylpyrrolidone bipolymeric systems. I. Rheological and mucoadhesive properties of formulations potentially useful for the treatment of dry-eye-syndrome, Eur. J. Pharm. Biopharm., 47 (2), 113-118.
70. Shibuya, T., Kashiwagi, K., and Tsukahara, S. (2003), Comparison of efficacy and tolerability between two gel-forming timolol maleate ophthalmic solutions in patients with glaucoma or ocular hypertension, Ophthalmologica, 217 (1), 31-38.
71. Rosenlund, E. F. (1996), The intraocular pressure lowering effect of timolol in gel-forming solution, Acta Ophthalmol. Scand., 74 (2), 160-162.
72. Stewart, W. C., Leland, T. M., Cate, E. A., and Stewart, J. A. (1998), Efficacy and safety of timolol solution once daily versus timolol gel in treating elevated intraocular pressure, J. Glaucoma, 7 (6), 402-407.
73. Shedden, A., Laurence, J., and Tipping, R. (2001), Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: A six-month, double-masked, multicenter study, Clin. Ther., 23 (3), 440-450.
74. Carlfors, J., Edsman, K., P etersson, R., and Jornving, K. (1998), Rheological evaluation of Gelrite(R) in situ gels for ophthalmic use, Eur. J. Pharm. Sci., 6 (2), 113-119.
75. Schenker, H. I., and Silver, L. H. (2000), Long-term intraocular pressure-lowering effi-cacy and safety of timolol maleate gel-forming solution 0.5% compared with timoptic XE 0.5% in a 12-month study, Am. J. Ophthalmol., 130 (2), 145-150.
76. Shedden, A. H., Laurence, J., Barrish, A., and Olah, T. V. (2001), Plasma timolol concentrations of timolol maleate: Timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily, Doc. Ophthalmol., 103 (1), 73-79.
77. Lindell, K., and Engstrom, S. (1993), In vitro release of timolol maleate from an in situ gelling polymer system, Int. J. Pharm., 95 (1-3), 219-228.
78. Rozier, A., Mazuel, C., Grove, J., and Plazonnet, B. (1989), Gelrite(R): A novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol, Int. J. Pharm., 57 (2), 163-168.
79. Balasubramaniam, J., Kant, S., and Pandit, J. K. (2003), In vitro and in vivo evaluation of the Gelrite gellan gum-based ocular delivery system for indomethacin, Acta Pharm., 53 (4), 251-261.
80. Sultana, Y., Aqil, M., and Ali, A. (2006), Ion-activated, Gelrite-based in situ ophthalmic gels of pefloxacin mesylate: Comparison with conventional eye drops, Drug Deliv., 13 (3), 215-219.
81. Liu, Z., Li, J., Nie, S., Liu, H., Ding, P., and Pan, W. (2006), Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin, Int. J. Pharm., 315 (1-2), 12-17.
82. Srividya, B., Cardoza, R. M., and Amin, P. D. (2001), Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system, J. Controlled Release, 73 (2-3), 205-211.
83. Cohen, S., Lobel, E., Trevgoda, A., and Peled, Y. (1997), A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye, J. Controlled Release, 44 (2-3), 201-208.
84. Demailly, P., Allaire, C., and Trinquand, C. (2001), Ocular hypotensive efficacy and safety of once daily carteolol alginate, Br. J. Ophthalmol., 85 (8), 921-924.
85. Cho, K. Y., Chung, T. W., Kim, B. C., Kim, M. K., Lee, J. H., Wee, W. R., et al. (2003), Release of ciprofloxacin from poloxamer-graft-hyaluronic acid hydrogels in vitro, Int. J. Pharm., 260 (1), 83-91.
86. Desai, S. D., and Blanchard, J. (1998), Evaluation of pluronic F127-based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model, J. Pharm. Sci., 87 (10), 1190-1195.
87. Lin, H. R., and Sung, K. C. (2000), Carbopol/pluronic phase change solutions for ophthalmic drug delivery, J. Controlled Release, 69 (3), 379-388.
88. Miyazaki, S., Suzuki, S., Kawasaki, N., Endo, K., Takahashi, A., and Attwood, D. (2001), In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride, Int. J. Pharm., 229 (1-2), 29-36.
89. El-Kamel, A. H. (2002), In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate, Int. J. Pharm., 241 (1), 47-55.
90. Wu, J., Su, Z.-G., and Ma, G.-H. (2006), A thermo-and pH-sensitive hydrogel composed of quaternized chitosan/glycerophosphate, Int. J. Pharm., 315 (1-2), 1-11.
91. Wei, G., Xu, H., Ding, P. T., Li, S. M., and Zheng, J. M. (2002), Thermosetting gels with modulated gelation temperature for ophthalmic use: The rheological and gamma scintigraphic studies, J. Controlled Release, 83 (1), 65-74.
92. Vandervoort, J., and Ludwig, A. (2004), Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use, Eur. J. Pharm. Biopharm., 57 (2), 251-261.
93. Zimmer, A. K., Maincent, P., Thouvenot, P., and Kreuter, J. (1994), Hydrocortisone delivery to healthy and inflamed eyes using a micellar polysorbate 80 solution or albumin nanoparticles, Int. J. Pharm., 110 (3), 211-222.
94. Zimmer, A. K., Zerbe, H., and Kreuter, J. (1994), Evaluation of pilocarpine-loaded albumin particles as drug delivery systems for controlled delivery in the eye I. In vitro and in vivo characterisation, J. Controlled Release, 32 (1), 57-70.
95. Zimmer, A. K., Chetoni, P., Saettone, M. F., Zerbe, H., and Kreuter, J. (1995), Evaluation of pilocarpine-loaded albumin particles as controlled drug delivery systems for the eye. II. Coadministration with bioadhesive and viscous polymers, J. Controlled Release, 33 (1), 31-46.
96. Mazor, Z., Ticho, U., Rehany, U., and Rose, L. (1979), Piloplex, a new long-acting pilocarpine polymer salt. B: Comparative study of the visual effects of pilocarpine and Piloplex eye drops, Br. J. Ophthalmol., 63 (1), 48-51.
97. Ticho, U., Blementhal, M., Zonis, S., Gal, A., Blank, I., and Mazor, Z. W. (1979), Piloplex, a new long-acting pilocarpine polymer salt. A: Long-term study, Br. J. Ophthalmol., 63 (1), 45-47.
98. Klein, H. Z., Lugo, M., Shields, M. B., Leon, J., and Duzman, E. (1985), A dose-response study of piloplex for duration of action, Am. J. Ophthalmol., 99 (1), 23-26.
99. Gurny, R. (1981), Preliminary study of prolonged acting drug delivery system for the treatment of glaucoma, Pharm. Acta Helv., 56 (4-5), 130-132.
100. Gurny, R., Boye, T., and Ibrahim, H. (1985), Ocular therapy with nanoparticulate systems for controlled drug delivery, J. Controlled Release, 2, 353-361.
101. Gurny, R., Ibrahim, H., Aebi, A., Buri, P., Wilson, C. G., Washington, N., et al. (1987), Design and evaluation of controlled release systems for the eye, J. Controlled Release, 6 (1), 367-373.
102. Marchal-Heussler, L., Orallo, F., Vila Jato, J. L., and Alonso, M. J. (1992), Colloidal drug delivery systems for the eye: A comparison of the efficacy of three different polymers: Polyisobutylcyanoacrylate, polylacticcoglycolic acid, poly-epsilon-caprolactone, STP Pharma Sci., 2, 98-104.
103. Marchal-Heussler, L., Sirbat, D., Hoffman, M., and Maincent, P. (1993), Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery, Pharm. Res., 10 (3), 386-390.
104. Harmia, T., Speiser, P., and Kreuter, J. (1986), Optimization of pilocarpine loading onto nanoparticles by sorption procedures, Int. J. Pharm., 33 (1-3), 45-54.
105. Diepold, R., Kreuter, J., Himber, J., Gurny, R., Lee, V. H., Robinson, J. R., et al. (1989), Comparison of different models for the testing of pilocarpine eyedrops using conventional eyedrops and a novel depot formulation (nanoparticles), Graefes Arch. Clin. Exp. Ophthalmol., 227 (2), 188-193.
106. Harmia, T., Speiser, P., and Kreuter, J. (1987), Nanoparticles as drug carriers in ophthalmology, Pharm. Acta Helv., 62 (12), 322-331.
107. Zimmer, A., Mutschler, E., Lambrecht, G., Mayer, D., and Kreuter, J. (1994), Pharmacokinetic and pharmacodynamic aspects of an ophthalmic pilocarpine nanoparticle-delivery-system, Pharm. Res., 11 (10), 1435-1442.
108. De Campos, A. M., Sanchez, A., and Alonso, M. J. (2001), Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A, Int. J. Pharm., 224(1-2), 159-168.
109. Calvo, P., Vila-Jato, J. L., and Alonso, M. J. (1997), Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers, Int. J. Pharm., 153 (1), 41-50.
110. De Campos, A. M., Sanchez, A., Gref, R., Calvo, P., and Alonso, M. J. (2003), The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa, Eur. J. Pharm. Sci., 20 (1), 73-81.
111. Giannavola, C., Bucolo, C., Maltese, A., Paolino, D., Vandelli, M. A., Puglisi, G., et al. (2003), Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability, Pharma. Res., 20 (4), 584-590.
112. Hsiue, G.-H., Hsu, S.-h., Yang, C.-C., Lee, S.-H., and Yang, I.-K. (2002), Preparation of controlled release ophthalmic drops, for glaucoma therapy using thermosensitive poly-N-isopropylacrylamide, Biomaterials, 23 (2), 457-462.
113. Pignatello, R., Bucolo, C., Ferrara, P., Maltese, A., Puleo, A., and Puglisi, G. (2002), Eudragit RS100(R) nanosuspensions for the ophthalmic controlled delivery of ibuprofen, Eur. J. Pharm. Sci., 16 (1-2), 53-61.
114. Bucolo, C., Maltese, A., Puglisi, G., and Pignatello, R. (2002), Enhanced ocular anti-inflammatory activity of ibuprofen carried by an eudragit RS100(R) nanoparticle suspension, Ophthal. Res., 34 (5), 319-323.
115. Pignatello, R., Bucolo, C., Spedalieri, G., Maltese, A., and Puglisi, G. (2002), Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application, Biomaterials, 23 (15), 3247-3255.
116. Khopade, A. J., and Jain, N. K. (1995), Self assembling nanostructures for sustained ophthalmic drug delivery, Pharmazie, 50 (12), 812-814.
117. Cavalli, R., Gasco, M. R., C hetoni, P., Burgalassi, S., and S aettone, M. F. (2002), Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin, Int. J. Pharm., 238 (1-2), 241-245.
118. Safwat, S. M., and Al-Kassas, R. S. (2002), Evaluation of gentamicin-Eudragit microspheres as ophthalmic delivery systems in inflamed rabbit's eyes, STP Pharma Sci., 12 (6), 357-361.
119. Giunchedi, P., Conte, U., Chetoni, P., and Saettone, M. F. (1999), Pectin microspheres as ophthalmic carriers for piroxicam: Evaluation in vitro and in vivo in albino rabbits, Eur. J. Pharm. Sci., 9 (1), 1-7.
120. Giunchedi, P., Chetoni, P., Conte, U., and Saettone, M. F. (2000), Albumin microspheres for ocular delivery of piroxicam, Pharm. Pharmacol. Commun., 6 (4), 149-153.
121. Davies, N. M., Farr, S. J., Hadgraft, J., and Kellaway, I. W. (1992), Evaluation of mucoadhesive polymers in ocular drug delivery. II. Polymer-coated vesicles, Pharm. Res., 9 (9), 1137-1144.
122. Durrani, A. M., Davies, N. M., Thomas, M., and Kellaway, I. W. (1992), Pilocarpine bioavailability from a mucoadhesive liposomal ophthalmic drug delivery system, Int. J. Pharm., 88 (1-3), 409-415.
123. Henriksen, I., Green, K. L., Smart, J. D., Smistad, G., and Karlsen, J. (1996), Bioadhesion of hydrated chitosans: An in vitro and in vivo study, Int. J. Pharm., 145 (1-2), 231-240.
124. Bochot, A., Fattal, E., Gulik, A., Couarraze, G., and Couvreur, P. (1998), Liposomes dispersed within a thermosensitive gel: A new dosage form for ocular delivery of oligonucleotides, Pharm. Res., 15 (9), 1364-1369.
125. Bochot, A., Fattal attal, E., Grossiord, J. L., Puisieux, F., and C ouvreur, P. (1998), Characterization of a new ocular delivery system based on a dispersion of liposomes in a thermosensitive gel, Int. J. Pharm., 162 (1-2), 119-127.
126. Bochot, A., Mashhour, B., Puisieux, F., Couvreur, P., and Fattal, E. (1998), Comparison of the ocular distribution of a model oligonucleotide after topical instillation in rabbits of conventional and new dosage forms, J. Drug Target., 6 (4), 309-313.
127. Nagarsenker, M. S., Londhe, V. Y., and Nadkarni, G. D. (1999), Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery, Int. J. Pharm., 190 (1), 63-71.
128. Aggarwal, D., and Kaur, I. P. (2005), Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system, Int. J. Pharm., 290 (1-2), 155-159.
129. Muchtar, S., Abdulrazik, M., Frucht-Pery, J., and Benita, S. (1997), Ex-vivo permeation study of indomethacin from a submicron emulsion through albino rabbit cornea, J. Controlled Release, 44 (1), 55-64.
130. Sznitowska, M., Zurowska-Pryczkowska, K., Dabrowska, E., and Janicki, S. (2000), Increased partitioning of pilocarpine to the oily phase of submicron emulsion does not result in improved ocular bioavailability, Int. J. Pharm., 202 (1-2), 161-164.
131. Haße, A., and Keipert, S. (1997), Development and characterisation of microemulsions for ocular application, Eur. J. Pham. Biopharm., 43 (2), 179-183.
132. Radomska, A., and Dobrucki, R. (2000), The use of some ingredients for microemulsion preparation containing retinol and its esters, Int. J. Pharm., 196 (2), 131-134.
133. Alany, R. G., Rades, T., Nicoll, J., Tucker, I. G., and Davies, N. M. (2006), W/O microemulsions for ocular delivery: Evaluation of ocular irritation and precorneal retention, J. Controlled Release, 111 (1-2), 145-152.
134. Kaback, M. B., Podos, S. M., Harbin, T. S. Jr,., Mandell, A., and Becker, B. (1976), The effects of dipivalyl epinephrine on the eye, Am. J. Ophthalmol., 81 (6), 768-772.
135. Wei, C. P., Anderson, J. A., and Leopold, I. (1978), Ocular absorption and metabolism of topically applied epinephrine and a dipivalyl ester of epinephrine, Invest. Ophthalmol. Vis. Sci., 17 (4), 315-321.
136. Jarvinen, T., Suhonen, P., Auriola, S., Vepsalainen, J., Peura, P., et al. (1991), O, O '-(1,4-Xylylene)bispilocarpic acid esters as new potential double prodrugs of pilocarpine for improved ocular delivery. Part 1. Synthesis and analysis, Int. J. Pharm., 75 (2-3), 249-258.
137. Tirucherai, G. S., Dias, C., and Mitra, A. K. (2002), Corneal permeation of ganciclovir: Mechanism of ganciclovir permeation enhancement by acyl ester prodrug design, J. Ocul. Pharmacol. Ther., 18 (6), 535-548.
138. Saettone, M. F., Chetoni, P., Cerbai, R., Mazzanti, G., and Braghiroli, L. (1996), Evaluation of ocular permeation enhancers: In vitro effects on corneal transport of four beta-blockers, and in vitro/in vivo toxic activity, Int. J. Pharm., 142 (1), 103-113.
139. Maestrelli, F., Mura, P., Casini, A., Mincione, F., Scozzafava, A., and Supuran, C. T. (2002), Cyclodextrin complexes of sulfonamide carbonic anhydrase inhibitors as long-lasting topically acting antiglaucoma agents, J. Pharm. Sci., 91 (10), 2211-2219.
140. Nijhawan, R., and Agarwal, S. P. (2003), Development of an ophthalmic formulation containing ciprofloxacin-hydroxypropyl-β-cyclodextrin complex, Boll. Chim. Farm., 142 (5), 214-219.
141. Aktas, Y., Unlu, N., Orhan, M., Irkec, M., and Hincal, A. A. (2003), Influence of hydroxypropyl beta-cyclodextrin on the corneal permeation of pilocarpine, Drug Dev. Ind. Pharm., 29 (2), 223-230.
142. Harwood, R. J., and Schwartz, J. B. (1982), Drug release from compression molded films: Preliminary studies with pilocarpine, Drug Dev. Ind. Pharm., 8 (5), 663-682.
143. Hsiue, G. H., Guu, J. A., and Cheng, C. C. (2001), Poly(2-hydroxyethyl methacrylate) film as a drug delivery system for pilocarpine, Biomaterials, 22 (13), 1763-1769.
144. Bharath, S., and Hiremath, S. R. (1999), Ocular delivery systems of pefloxacin mesylate, Pharmazie, 54 (1), 55-58.
145. Sultana, Y., Aqil, M., and Ali, A. (2005), Ocular inserts for controlled delivery of pefloxacin mesylate: Preparation and evaluation, Acta Pharma., 55 (3), 305-314.
146. Zimmermann, C., Drewe, J., Flammer, J., and Shaarawy, T. (2004), In vitro release of mitomycin C from collagen implants, Curr. Eye Res., 28 (1), 1-4.
147. Vasantha, V., Sehgal, P. K., and Rao, K. P. (1988), Collagen ophthalmic inserts for pilocarpine drug delivery system, Int. J. Pharm., 47 (1-3), 95-102.
148. Saettone, M. F., Giannaccini, B., Chetoni, P., Galli, G., and Chiellini, E. (1984), Vehicle effects in ophthalmic bioavailability: An evaluation of polymeric inserts containing pilocarpine, J. Pharm. Pharmacol., 36 (4), 229-234.
149. Saettone, M. F., Torracca, M. T., Pagano, A., Giannaccini, B., Rodriguez, L., and Cini, M. (1992), Controlled release of pilocarpine from coated polymeric ophthalmic inserts prepared by extrusion, Int. J. Pharm., 86 (2-3), 159-166.
150. Saettone, M. F., Chetoni, P., Bianchi, L. M., Giannaccini, B., Conte, U., and Sangalli, M. E. (1995), Controlled release of timolol maleate from coated ophthalmic mini-tablets prepared by compression, Int. J. Pharm., 126 (1-2), 79-82.
151. Sasaki, H., Tei, C., Nishida, K., and Nakamura, J. (1993), Drug release from an ophthalmic insert of a beta-blocker as an ocular drug delivery system, J. Controlled Release, 27 (2), 127-137.
152. Sasaki, H., Nagano, T., Sakanaka, K., Kawakami, S., Nishida, K., Nakamura, J., et al. (2003), One-side-coated insert as a unique ophthalmic drug delivery system, J. Controlled Release, 92 (3), 241-247.
153. Charoo, N. A., Kohli, K., Ali, A., and Anwer, A. (2003), Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: In vitro and in vivo studies, Drug Dev. Ind. Pharm., 29 (2), 215-221.
154. Pijls, R. T., Sonderkamp, T., Daube, G. W., Krebber, R., Hanssen, H. H. L., Nuijts, R. M. M. A., et al. (2005), Studies on a new device for drug delivery to the eye, Eur. J. Pharm. Biopharm., 59 (2), 283-288.
155. Lux, A., Maier, S., Dinslage, S., Suverkrup, R., and Diestelhorst, M. (2003), A comparative bioavailability study of three conventional eye drops versus a single lyophilisate, Br. J. Ophthalmol., 87 (4), 436-440.
156. Dinslage, S., Diestelhorst, M., Weichselbaum, A., and Suverkrup, R. (2002), Lyophilisates for drug delivery in Ophthalmology: Pharmacokinetics of fluorescein in the human anterior segment, Br. J. Ophthalmol., 86 (10), 1114-1117.
157. Ceulemans, J., Vermeire, A., Adriaens, E., Remon, J. P., and Ludwig, A. (2001), Evaluation of a mucoadhesive tablet for ocular use, J. Controlled Release, 77 (3), 333-344.
158. Weyenberg, W., Vermeire, A., Remon, J. P., and Ludwig, A. (2003), Characterization and in vivo evaluation of ocular bioadhesive minitablets compressed at different forces, J. Controlled Release, 89 (2), 329-340.
159. Baeyens, V., Kaltsatos, V., Boisrame, B., Fathi, M., and Gurny, R. (1998), Evaluation of soluble Bioadhesive Ophthalmic Drug Inserts (BODI) for prolonged release of gentamicin: Lachrymal pharmacokinetics and ocular tolerance, J. Ocul. Pharmacol. Ther., 14 (3), 263-272.
160. Baeyens, V., Felt-Baeyens, O., Rougier, S., Pheulpin, S., Boisrame, B., and Gurny, R. (2002), Clinical evaluation of bioadhesive ophthalmic drug inserts (BODI(R)) for the treatment of external ocular infections in dogs, J. Controlled Release, 85 (1-3), 163-168.
161. Chetoni, P., Di Colo, G., Grandi, M., Morelli, M., Saettone, M. F., and Darougar, S. (1998), Silicone rubber/hydrogel composite ophthalmic inserts: Preparation and preliminary in vitro/in vivo evaluation, Eur. J. Pharm. Biopharm., 46 (1), 125-132.
162. Di Colo, G., and Zambito, Y. (2002), A study of release mechanisms of different ophthalmic drugs from erodible ocular inserts based on poly(ethylene oxide), Eur. J. Pharm. Biopharm., 54 (2), 193-199.
163. Di Colo, G., Burgalassi, S., Chetoni, P., Fiaschi, M. P., Zambito, Y., and Saettone, M. F. (2001), Relevance of polymer molecular weight to the in vitro/in vivo performances of ocular inserts based on poly(ethylene oxide), Int. J. Pharm., 220 (1-2), 169-177.
164. Di Colo, G., Burgalassi, S., Chetoni, P., Fiaschi, M. P., Zambito, Y., and Saettone, M. F. (2001), Gel-forming erodible inserts for ocular controlled delivery of ofloxacin, Int. J. Pharm., 215 (1-2), 101-111.
165. Di Colo, G., Zambito, Y., Burgalassi, S., Serafini, A., and Saettone, M. F. (2002), Effect of chitosan on in vitro release and ocular delivery of ofloxacin from erodible inserts based on poly(ethylene oxide), Int. J. Pharm., 248 (1-2), 115-122.
166. Hornof, M., Weyenberg, W., Ludwig, A., and Bernkop-Schnurch, A. (2003), Mucoadhesive ocular insert based on thiolated poly(acrylic acid): Development and in vivo evaluation in humans, J. Controlled Release, 89 (3), 419-428.
167. Frucht-Pery, J., Mechoulam, H., Siganos, C. S., Ever-Hadani, P., Shapiro, M., and Domb, A. (2004), Iontophoresis-gentamicin delivery into the rabbit cornea, using a hydrogel delivery probe, Exper. Eye Res., 78 (3), 745-749.
168. Vandamme, T. F., and Brobeck, L. (2005), P oly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide, J. Controlled Release, 102 (1), 23-38.
169. Lang, J. C. (1995), Ocular drug delivery conventional ocular formulations, Adv. Drug Deliv. Rev., 16 (1), 39-43.
170. Fitzgerald, P., and Wilson, C. G. (1994), Polymeric systems for ophthalmic drug delivery, in Dimitriuitra S., Ed., Polymeric Biomaterials, Marcel Dekker, New York, pp. 373-398.
171. Kupferman, A., Pratt, M. V., Suckewer, K., and Leibowitz, H. M. (1974), Topically applied steroids in corneal disease. 3. The role of drug derivative in stromal absorption of dexamethasone, Arch. Ophthalmol., 91 (5), 373-376.
172. Wilson, C. G., Olejnik, O., and Hardy, J. G. (1983), Precorneal drainage of polyvinyl alcohol solutions in the rabbit assessed by gamma scintigraphy, J. Pharm. Pharmacol., 35 (7), 451-454.
173. Olejnik, O., and Weisbecker, C. A. (1990), Ocular bioavailability of topical prednisolone preparations, Clin. Ther., 12 (1), 2-11.
174. Davies, N. M. (2000), Biopharmaceutical considerations in topical ocular drug delivery, Clin. Exp. Pharmacol. Physiol., 27 (7), 558-562.
175. Davies, N. M., Wang, G., and Tucker, I. G. (1997), Evaluation of a hydrocortisone/hydroxypropyl-[beta]-cyclodextrin solution for ocular drug delivery, Int. J. Pharm., 156 (2), 201-209.
176. Olejnik, O. (1993), Conventional systems in ophthalmic drug delivery, in Mitra, A. K., Ed., Ophthalmic Drug Delivery Systems, Marcel Dekker, New York, pp. 177-198.
177. Schoenwald, R. D., and Stewart, P. (1980), Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits, J. Pharm. Sci., 69 (4), 391-394.
178. MacKeen, D. L. (1980), Aqueous formulations and ointments, Int. Ophthalmol. Clin., 20 (3), 79-92.
179. Sieg, J. W., and Robinson, J. R. (1977), Vehicle effects on ocular drug bioavailability II: Evaluation of pilocarpine, J. Pharm. Sci., 66 (9), 1222-1228.
180. Greaves, J. L., Wilson, C. G., and Birmingham, A. T. (1993), Assessment of the precorneal residence of an ophthalmic ointment in healthy subjects, Br. J. Clin. Pharmacol., 35 (2), 188-192.
181. Lee, V. H., and Robinson, J. R. (1986), Topical ocular drug delivery: Recent developments and future challenges, J. Ocul. Pharmacol., 2 (1), 67-108.
182. Saettone, M. F., Giannaccini, B., Teneggi, A., Savigni, P., and Tellini, N. (1982), Vehicle effects on ophthalmic bioavailability: The influence of different polymers on the activity of pilocarpine in rabbit and man, J. Pharm. Pharmacol., 34 (7), 464-466.
183. Trueblood, J. H., Rossomondo, R. M., Wilson, L. A., and Carlton, W. H. (1975), Corneal contact times of ophthalmic vehicles. Evaluation by microscintigraphy, Arch. Ophthalmol., 93 (2), 127-130.
184. Patton, T. F., and Robinson, J. R. (1976), Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes, J. Pharm. Sci., 65 (9), 1295-1301.
185. Patton, T. F., and Robinson, J. R. (1975), Ocular evaluation of polyvinyl alcohol vehicle in rabbits, J. Pharm. Sci., 64 (8), 1312-1316.
186. Tiffany, J. M. (1991), The viscosity of human tears, Int. Ophthalmol., 15 (6), 371-376.
187. Van Ooteghem, M. (1987), Factors influencing the retention of ophthalmic solutions on the eye surface, in Saettone, M. F., Bucci, M., and Speiser, P., Eds., Ophthalmic Drug Delivery: Biopharmaceutical, Technological and Clinical Aspects, Vol. 11, Livinia, Padova, pp. 7-17
188. Ludwig, A., van Haeringen, N. J., Bodelier, V. M., and Van Ooteghem, M. (1992), Relationship between precorneal retention of viscous eye drops and tear fluid composition, Int. Ophthalmol., 16 (1), 23-26.
189. Greaves, J. L., Olejnik, O., and Wilson, C. G. (1992), Polymers and the precorneal tear film, STP Pharma Sci., 2, 13-33.
190. Park, H., and Robinson, J. R. (1987), Mechanisms of mucoadhesion of poly(acrylic acid) hydrogels, Pharm. Res., 4 (6), 457-464.
191. Robinson, J. R., and Mlynek, G. M. (1995), Bioadhesive and phase-change polymers for ocular drug delivery, Adv. Drug Deliv. Rev., 16 (1), 45-50.
192. Lehr, C.-M., Bouwstra, J. A., Schacht, E. H., and Junginger, H. E. (1992), In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers, Int. J. Pharm., 78 (1-3), 43-48.
193. Park, K., and Robinson, J. R. (1984), Bioadhesive polymers as platforms for oral-controlled drug Delivery: Method to study bioadhesion, Int. J. Pharm., 19 (2), 107-127.
194. Meseguer, G., Gurny, R., Buri, P., Rozier, A., and Plazonnet, B. (1993), Gamma scintigraphic study of precorneal drainage and assessment of miotic response in rabbits of various ophthalmic formulations containing pilocarpine, Int. J. Pharm., 95 (1-3), 229-234.
195. Thermes, F., Rozier, A., Plazonnet, B., and Grove, J. (1992), Bioadhesion: The effect of polyacrylic acid on the ocular bioavailability of timolol, Int. J. Pharm., 81 (1), 59-65.
196. Duchene, D., Touchard, F., and Peppas, N. A. (1988), Pharmaceutical and medical aspects of bioadhesive systems for drug administration, Drug Dev. Ind. Pharm., 14 (2-3), 283-318.
197. Calonge, M. (2001), The treatment of dry eye, Surv. Ophthalmol., 45 (Suppl. 2), S227-S239.
198. Zignani, M., Tabatabay, C., and Gurny, R. (1995), Topical semi-solid drug delivery: Kinetics and tolerance of ophthalmic hydrogels, Adv. Drug Deliv. Rev., 16 (1), 51-60.
199. Krauland, A. H., Leitner, V. M., and Bernkop-Schnurch, A. (2003), Improvement in the in situ gelling properties of deacetylated gellan gum by the immobilization of thiol groups, J. Pharm. Sci., 92 (6), 1234-1241.
200. Gurny, R., Ibrahim, H., and Buri, P. (1993), The development and use of in situ formed gels, triggered by pH, in Edman, P., Ed., Biopharmaceutics of Ocular drug Delivery, CRC Press, Boca Raton, FL, pp. 81-90.
201. Greaves, J. L., Wilson, C. G., Rozier, A., Grove, J., and Plazonnet, B. (1990), Scintigraphic assessment of an ophthalmic gelling vehicle in man and rabbit, Curr. Eye Res., 9 (5), 415-420.
202. Furrer, P., Plazonnet, B., Mayer, J. M., and Gurny, R. (2000), Application of in vivo confocal microscopy to the objective evaluation of ocular irritation induced by surfactants, Int. J. Pharm., 207 (1-2), 89-98.
203. Kumar, S., Haglund, B. O., and H immelstein, K. J. (1994), In situ-forming gels for ophthalmic drug delivery, J. Ocul. Pharmacol., 10 (1), 47-56.
204. Calvo, P., Alonso, M. J., Vila-Jato, J. L., and Robinson, J. R. (1996), Improved ocular bioavailability of indomethacin by novel ocular drug carriers, J. Pharm. Pharmacol., 48 (11), 1147-1152.
205. Lallemand, F., Felt-Baeyens, O., Besseghir, K., Behar-Cohen, F., and G urny, R. (2003), Cyclosporine A delivery to the eye: A pharmaceutical challenge, Eur. J. Pharm. Biopharm., 56 (3), 307-318.
206. Kreuter, J. (1990), Nanoparticles as bioadhesive ocular drug delivery systems, in Lenaerts, V., and Gurny, R., Eds., Bioadhesive Drug Delivery Systems, CRC Press, Boca Raton, FL, pp. 203-212.
207. Mainardes, R. M., and Silva, L. P. (2004), Drug delivery systems: Past, present, and future, Curr. Drug Targets, 5 (5), 449-455.
208. Ding, S. (1998), Recent developments in ophthalmic drug delivery, P harm. Sci. Technol. Today, 1 (8), 328-335.
209. Kaur, I. P., and Kanwar, M. (2002), Ocular preparations: The formulation approach, Drug Dev. Ind. Pharm., 28 (5), 473-493.
210. Meisner, D., and Mezei, M. (1995), Liposome ocular delivery systems, Adv. Drug Deliv. Rev., 16 (1), 75-93.
211. El-Gazayerly, O. N., and Hikal, A. H. (1997), Preparation and evaluation of acetazolamide liposomes as an ocular delivery system, Int. J. Pharm., 158 (2), 121-127.
212. Fresta, M., Panico, A. M., Bucolo, C., Giannavola, C., and Puglisi, G. (1999), Characterization and in-vivo ocular absorption of liposome-encapsulated acyclovir, J. Pharm. Pharmacol., 51 (5), 565-576.
213. Law, S. L., Huang, K. J., and Chiang, C. H. (2000), Acyclovir-containing liposomes for potential ocular delivery: Corneal penetration and absorption, J. Controlled Release, 63 (1-2), 135-140.
214. Alonso, M. J., and Sanchez, A. (2003), The potential of chitosan in ocular drug delivery, J. Pharm. Pharmacol., 55 (11), 1451-1463.
215. Carafa, M., Santucci, E., and Lucania, G. (2002), Lidocaine-loaded non-ionic surfactant vesicles: Characterization and in vitro permeation studies, Int. J. Pharm., 231 (1), 21-32.
216. Vyas, S. P., Mysore, N., Jaitely, V., and Venkatesan, N. (1998), Discoidal niosome based controlled ocular delivery of timolol maleate, Pharmazie, 53 (7), 466-469.
217. Schmalfuss, U., Neubert, R., and Wohlrab, W. (1997), Modification of drug penetration into human skin using microemulsions, J. Controlled Release, 46 (3), 279-285.
218. Bagwe, R. P., Kanicky, J. R., Palla, B. J., Patanjali, P. K., and Shah, D. O. (2001), Improved drug delivery using microemulsions: Rationale, recent progress, and new horizons, Crit. Rev. Ther. Drug Carrier Syst., 18 (1), 77-140.
219. Attwood, D. (1994), Microemulsions, in Kreuter, J., Ed., Colloidal Drug Delivery Systems, Marcel Dekker, New York, pp. 31-71.
220. Benita, S., and Levy, M. Y. (1993), Submicron emulsions as colloidal drug carriers for intravenous administration: Comprehensive physicochemical characterization, J. Pharm. Sci., 82 (11), 1069-1079.
221. Gasco, M. R., Gallarate, M., Trotta, M., Bauchiero, L., Chiappero, O., et al. (1989), Microemulsions as topical delivery vehicles: Ocular administration of timolol, J. Pharm. Biomed. Anal., 7 (4), 433-439.
222. Beilin, M., Bar-Ilan, A., A mselem, S., Schwarz, J., Yogev, A., and Neumann, R. (1995), Ocular retention time of submicron emulsion (SME) and the miotic response to pilocarpine delivered in SME, Invest. Ophthalmol. Vis. Sci., 36 (4), 166.
223. Esfand, R., and Tomalia, D. A. (2001), Poly(amidoamine) (PAMAM) dendrimers: From biomimicry to drug delivery and biomedical applications, Drug Discov. Today, 6 (8), 427-436.
224. Cloninger, M. J. (2002), Biological applications of dendrimers, Curr. Opin. Chem. Biol., 6 (6), 742-748.
225. Patri, A. K., Majoros, I. J., Baker, J., and James R. (2002), Dendritic polymer macromolecular carriers for drug delivery, Curr. Opin. Chem. Biol., 6 (4), 466-471.
226. Stella, V. J., and Himmelstein, K. J. (1980), Prodrugs and site-specific drug delivery, J. Med. Chem., 23 (12), 1275-1282.
227. Lee, V. H. (1993), Improved ocular drug delivery by use of chemical modifications (prodrugs), in Edman, P., Ed., Biopharmaceutics of Ocular Drug Delivery, CRC Press, Boca Raton, FL, pp. 121-143.
228. Lee, V. H. (1983), Esterase activities in adult rabbit eyes, J. Pharm. Sci., 72 (3), 239-244.
229. Redell, M. A., Yang, D. C., and Lee, V. H. L. (1983), The role of esterase activity in the ocular disposition of dipivalyl epinephrine in rabbits, Int. J. Pharm., 17 (2-3), 299-312.
230. Jarvinen, T., and Jarvinen, K. (1996), Prodrugs for improved ocular drug delivery, Adv. Drug Deliv. Rev., 19 (2), 203-224.
231. Sasaki, H., Igarashi, Y., Nagano, T., Nishida, K., and Nakamura, J. (1995), Different effects of absorption promoters on corneal and conjunctival penetration of ophthalmic beta-blockers, Pharm. Res., 12 (8), 1146-1150.
232. Hochman, J., and Artursson, P. (1994), Mechanisms of absorption enhancement and tight junction regulation, J. Controlled Release, 29 (Mar.), 253-267.
233. Grass, G. M., and Robinson, J. R. (1984), Relationship of chemical structure to corneal penetration and influence of low-viscosity solution on ocular bioavailability, J. Pharm. Sci., 73 (8), 1021-1027.
234. Szejtli, J. (1994), Medicinal applications of cyclodextrins, Med. Res. Rev., 14 (3), 353-386.
235. Sasaki, H., Yamamura, K., Nishida, K., Nakamura, J., and Ichikawa, M. (1996), Delivery of drugs to the eye by topical application, Prog. Retin. Eye Res., 15 (2), 583-620.
236. Jarvinen, K., Jarvinen, T., Thompson, D. O., and Stella, V. J. (1994), The effect of a modified beta-cyclodextrin, SBE4-beta-CD, on the aqueous stability and ocular absorption of pilocarpine, Curr. Eye Res., 13 (12), 897-905.
237. Jarho, P., Jarvinen, K., Urtti, A., Stella, V. J., and Jarvinen, T. (1996), Modified beta-cyclodextrin (SBE7-beta-CyD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits, J. Pharm. Pharmacol., 48 (3), 263-269.
238. Sultana, Y., Jain ain, R., Aqil, M., and Ali, A. (2006), Review of ocular drug delivery, C urr. Drug Deliv., 3 (2), 207-217.
239. Ranade, V. V., and Hollinger, M. A. (2003), Intranasal and ocular drug delivery. in Drug Delivery Systems, 2nd ed., CRC Press, Boca Raton, FL, pp. 249-287.
240. Lee, V. H. (1990), New directions in the optimization of ocular drug delivery, J. Ocul. Pharmacol., 6 (2), 157-164.